@CKD_ce (@ckd_ce) header
@CKD_ce (@ckd_ce) profile picture

Your source for joint-accredited serialized tweetorials in the CKD space! See all tweetorials--and still earn credit from AcademicCME--at https://teapaw.org/t.co/bUHAMqZzgE

Joined July 2021
Photo by @CKD_ce (@ckd_ce)Photo by @CKD_ce (@ckd_ce)Photo by @CKD_ce (@ckd_ce)Photo by @CKD_ce (@ckd_ce)Photo by @CKD_ce (@ckd_ce)Photo by @CKD_ce (@ckd_ce)Photo by @CKD_ce (@ckd_ce)Photo by @CKD_ce (@ckd_ce)Photo by @CKD_ce (@ckd_ce)Photo by @CKD_ce (@ckd_ce)
8/8: Click on this video for a full summary of the trial results! #SponsoredbyCleerly
14
33
2,397
7/8: In #PARAMOUNT, plaque-based care produced a win ratio of 2.0 versus usual care for the prespecified hierarchical composite. The difference was driven primarily by greater diagnostic certainty and lower LDL-C, important context when interpreting the overall trial result.
1
6
20
2,303
6/8: Two tiers drove this result: ⬆️diagnostic certainty and plaque image-guided ⬇️LDL-C. In addition, plaque-based care did NOT ⬆️% of pts referred for #angio nor were invasive procedures ⬆️. BUT . . . can ⬇️unnecessary procedures (cath without finding #CAD):
1
5
21
2,138
5/8: A #WinRatio of 1.0 ➡️no advantage for either arm. WR 1.2 ➡️test treatment has 20% more wins than losses; 1.5 ➡️test treatment has 50% more wins than losses; 2.0 ➡️test treatment has twice as many wins as losses. In #PARAMOUNT, WR = 2.0
1
16
36
2,079
4/8: #WinRatio allows a clinical trial to assess several different measures of treatment benefit simultaneously, without treating all outcomes as equally important. The win ratio is the number of comparisons won by the experimental treatment divided by the number lost.
1
4
22
2,077
3/8: A hierarchical #WinRatio was calculated for each plaque-based care patient vs each usual care patient for 4 outcomes, ranked by clinical priority:
1
6
8
2,221
2/8: #CCTA + #AI-QCT plaque & ischemia analysis was compared 1:1 to usual care (functional stress test) in stable symptomatic pts w/suspected #CAD. Image guidance informed stage-based medical therapy & revasc decisions; usual care was guideline-based per treating physician.
1
6
21
2,323
1/8: The #PARAMOUNT trial of #coronary plaque-based care was presented this morning at #AHA26. Here are the key findings and some context for interpreting the results. The trial and this post were sponsored by @CleerlyHealth, for whom I serve as a consultant.
2
25
53
4,237
8/8: Click on this video for a full summary of the trial results! #SponsoredbyCleerly
17
40
2,107
7/8: So what did we learn? In stable symptomatic pts with suspected #CAD, #coronary #plaque-based care was 2x more likely to result in favorable outcomes than usual guidelines-based care, driven mostly by ⬆️diagnostic certainty and ⬇️LDL_C levels.
2
8
20
2,132
6/8: Two tiers drove this result: ⬆️diagnostic certainty and plaque image-guided ⬇️LDL-C. In addition, plaque-based care did NOT ⬆️% of pts referred for #angio nor were invasive procedures ⬆️. BUT . . . can ⬇️unnecessary procedures (cath without finding #CAD):
1
6
21
1,875
5/8: A #WinRatio of 1.0 ➡️no advantage for either arm. WR 1.2 ➡️test treatment has 20% more wins than losses; 1.5 ➡️test treatment has 50% more wins than losses; 2.0 ➡️test treatment has twice as many wins as losses. In #PARAMOUNT, WR = 2.0
1
12
24
1,839
4/8: #WinRatio allows a clinical trial to assess several different measures of treatment benefit simultaneously, without treating all outcomes as equally important. The win ratio is the number of comparisons won by the experimental treatment divided by the number lost.
1
6
18
1,778
3/8: A hierarchical #WinRatio was calculated for each plaque-based care patient vs each usual care patient for 4 outcomes, ranked by clinical priority:
1
7
13
1,876
2/8: #CCTA + #AI-QCT plaque & ischemia analysis was compared 1:1 to usual care (functional stress test) in stable symptomatic pts w/suspected #CAD. Image guidance informed stage-based medical therapy & revasc decisions; usual care was guideline-based per treating physician.
1
7
27
2,006
1/8: I am pleased to share with you the top-line results from the #PARAMOUNT trial of #coronary #plaque-based care that were presented this morning at #AHA26! The trial was supported by @Cleerlyhealth, to which I am a consultant. Here are the essentials:
4
28
3
95
4,109
11b) . . . the first Ph 3 results for #enlicitide, the leading candidate oral #PSCK9i, shown in early trials to ⬇️LDL by as much as 60%. PR just after ESC ➡️at AHA we'll see positive LLT results on that drug in the #CORALreef program. #LBCTs are scheduled to be presented.
1
1
42
1,170
@CKD_ce retweeted
Replying to @onc_ce @harrisoncn1
42) Congratulations! You are up to date from #EHA26 on advances in therapy for #anemia associated with #myelofibrosis, AND you also just earned 1 hour of 🆓CE/#CME credit! Claim your certificate now at oncologytweetorials-ce.com/m…. Many thanks to our 🏆expert faculty @harrisoncn1!
6
18
1,176
@CKD_ce retweeted
22b) Duration of these responses, as well as the reduction in TB ≥ 50% with ≥ 4 units, was longer with #luspatercept compared with placebo
1
3
6
896
@CKD_ce retweeted
20) So now #EHA2026: On 13 June, Francesco Passamonti presented the updated results…. And here they are
1
5
6
903